Sponsor & Developer Portfolio

Sanofi

Clinical development pipeline, platform architecture, and registered trial tracking for Sanofi vaccine candidates.

Candidates

Target Diseases

Linked Studies

Development Phase Distribution

Discontinued / Inactive: 12 Phase 3 Clinical Trial: 6 Phase 2 Clinical Trial: 6 Phase 1 Clinical Trial: 3

Platform Technologies

Biological (unspecified platform): 12 Conjugate vaccine: 6 mRNA: 5 Inactivated: 2 Protein / subunit: 1 Toxoid: 1

Target Pathogens & Indications

Acne COVID-19 Chlamydia Trachomatis Immunization Clostridium Difficile Infection Dengue Genital Herpes HIV Influenza Melanoma Meningococcal disease Pneumococcal disease RSV Smallpox Yellow fever

Vaccine Pipeline Candidates (27)

Detailed candidate profiles, clinical phases, target indications, and anticipated milestones.

View Global Pipeline Matrix →

Discontinued / Inactive ctgov-acam1000-sanofi-pasteur-a-sanofi-company

ACAM1000

Target: Smallpox

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2003-03 (registry estimate)

View Full Clinical Profile →

Discontinued / Inactive ctgov-c-difficile-toxoid-vaccine-sanofi-pasteur-a-sanofi-company

C. difficile Toxoid Vaccine

Target: Clostridium Difficile Infection

Platform: Toxoid

Key Milestone: Primary completion (most advanced trial): 2018-06-12 (registry estimate)

View Full Clinical Profile →

Discontinued / Inactive ctgov-cyd-dengue-vaccine-sanofi-pasteur-a-sanofi-company

CYD Dengue Vaccine

Target: Dengue

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2019-12-10 (registry estimate)

View Full Clinical Profile →

Discontinued / Inactive ctgov-hsv-2-formulation-1-sanofi-pasteur-a-sanofi-company

HSV 2 Formulation 1

Target: Genital Herpes

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2021-05-19 (registry estimate)

View Full Clinical Profile →

Discontinued / Inactive ctgov-alvac-2-melanoma-multi-antigen-therapeutic-vaccine-sanofi-pasteu

Intron A, Interferon alpha -2b

Target: Melanoma

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2010-04 (registry estimate)

View Full Clinical Profile →

Discontinued / Inactive ctgov-mva-smallpox-vaccine-sanofi-pasteur-a-sanofi-company

MVA Smallpox Vaccine

Target: HIV

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2007-07 (registry estimate)

View Full Clinical Profile →

Discontinued / Inactive ctgov-sars-cov-2-mrna-vaccine-formulation-1-sanofi-pasteur-a-sanofi-co

Placebo (0.9% normal saline)

Target: COVID-19

Platform: mRNA

Key Milestone: Primary completion (most advanced trial): 2022-06-27 (registry estimate)

View Full Clinical Profile → Disease Hub →

Discontinued / Inactive ctgov-quadrivalent-influenza-vaccine-split-virion-inactivated-high-dos

Quadrivalent Influenza Vaccine (split virion, inactivated) High-Dose (QIV-HD)

Target: Influenza

Platform: Inactivated

Key Milestone: Primary completion (most advanced trial): 2020-05-31 (registry estimate)

View Full Clinical Profile → Disease Hub →

Discontinued / Inactive ctgov-quadrivalent-influenza-vaccine-high-dose-sanofi-pasteur-a-sanofi

Quadrivalent influenza vaccine, high-dose

Target: Influenza

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2021-06-02 (registry estimate)

View Full Clinical Profile → Disease Hub →

Discontinued / Inactive ctgov-recombinant-influenza-vaccine-riv4-sanofi-pasteur-a-sanofi-compa

Recombinant influenza vaccine (RIV4)

Target: Influenza

Platform: Protein / subunit

Key Milestone: Primary completion (most advanced trial): 2023-10-03 (registry estimate)

View Full Clinical Profile → Disease Hub →

Discontinued / Inactive ctgov-trivalent-inactivated-influenza-vaccine-high-dose-sanofi

Trivalent inactivated influenza vaccine

Target: Influenza

Platform: Inactivated

Key Milestone: Primary completion (most advanced trial): 2011-05 (registry estimate)

View Full Clinical Profile → Disease Hub →

Discontinued / Inactive ctgov-vaccine-diluent-buffer-sanofi

Vaccine diluent buffer

Target: Clostridium Difficile Infection

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2006-06 (registry estimate)

View Full Clinical Profile →

Phase 1 Clinical Trial ctgov-h5-flu-investigational-medical-product-imp-1-sanofi

H5 Flu IMP 2

Target: Influenza

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2027-04-04 (registry estimate)

View Full Clinical Profile → Disease Hub →

Phase 1 Clinical Trial ctgov-vxb-241-60-mcg-low-dose-sanofi

VXB-241 240 mcg

Target: RSV

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2025-02-14 (registry estimate)

View Full Clinical Profile → Disease Hub →

Phase 1 Clinical Trial ctgov-trivalent-rsv-hmpv-piv3-vaccine-candidate-sanofi

bivalent (RSV/hMPV) unlicensed comparator

Target: RSV

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2026-04-21 (registry estimate)

View Full Clinical Profile → Disease Hub →

Phase 2 Clinical Trial ctgov-acne-mrna-vaccine-sanofi-pasteur-a-sanofi-company

Acne mRNA vaccine

Target: Acne

Platform: mRNA

Key Milestone: Primary completion (most advanced trial): 2028-11-30 (registry estimate)

View Full Clinical Profile →

Phase 2 Clinical Trial ctgov-chlamydia-mrna-vaccine-sanofi

Chlamydia mRNA Vaccine

Target: Chlamydia Trachomatis Immunization

Platform: mRNA

Key Milestone: Primary completion (most advanced trial): 2028-01-03 (registry estimate)

View Full Clinical Profile →

Phase 2 Clinical Trial ctgov-investigational-hmpv-rsv-vaccine-sanofi-pasteur-a-sanofi-company

Licensed RSV Vaccine

Target: RSV

Platform: mRNA

Key Milestone: Primary completion (most advanced trial): 2027-01-18 (registry estimate)

View Full Clinical Profile → Disease Hub →

Phase 2 Clinical Trial ctgov-pentavalent-meningococcal-abcyw-vaccine-sanofi-pasteur-a-sanofi-

MenACYW conjugate vaccine

Target: Meningococcal disease

Platform: Conjugate vaccine

Key Milestone: Primary completion (most advanced trial): 2027-05-17 (registry estimate)

View Full Clinical Profile → Disease Hub →

Phase 2 Clinical Trial ctgov-pandemic-flu-h5-ha-mrna-sd2-vaccine-sanofi

Pandemic flu H5 HA mRNA SD2 vaccine

Target: Influenza

Platform: mRNA

Key Milestone: Primary completion (most advanced trial): 2026-12-01 (registry estimate)

View Full Clinical Profile → Disease Hub →

Phase 2 Clinical Trial ctgov-yellow-fever-vaccine-produced-on-serum-free-vero-cells-sanofi-pa

Yellow fever vaccine

Target: Yellow fever

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2022-06-24 (registry estimate)

View Full Clinical Profile → Disease Hub →

Phase 3 Clinical Trial ctgov-menacyw-conjugate-vaccine-sanofi

MenAC conjugate vaccine

Target: Meningococcal disease

Platform: Conjugate vaccine

Key Milestone: Primary completion (most advanced trial): 2026-05-01 (registry estimate)

View Full Clinical Profile → Disease Hub →

Phase 3 Clinical Trial ctgov-meningococcal-polysaccharide-serogroups-a-c-w-and-y-tetanus-toxo

Meningococcal Polysaccharide (Serogroups A, C, W, and Y) Tetanus Toxoid Conjugate Vaccine

Target: Meningococcal disease

Platform: Conjugate vaccine

Key Milestone: Primary completion (most advanced trial): 2023-03-09 (registry estimate)

View Full Clinical Profile → Disease Hub →

Phase 3 Clinical Trial ctgov-pcv21-sanofi

PCV21

Target: Pneumococcal disease

Platform: Conjugate vaccine

Key Milestone: Primary completion (most advanced trial): 2027-01-07 (registry estimate)

View Full Clinical Profile → Disease Hub →

Phase 3 Clinical Trial ctgov-pcv21-vaccine-sanofi-pasteur-a-sanofi-company

RotaTeq

Target: Pneumococcal disease

Platform: Conjugate vaccine

Key Milestone: Primary completion (most advanced trial): 2027-05-17 (registry estimate)

View Full Clinical Profile → Disease Hub →

Phase 3 Clinical Trial ctgov-pcv21-vaccine-sanofi

Rotarix

Target: Pneumococcal disease

Platform: Conjugate vaccine

Key Milestone: Primary completion (most advanced trial): 2027-09-10 (registry estimate)

View Full Clinical Profile → Disease Hub →

Phase 3 Clinical Trial ctgov-yellow-fever-vaccine-live-sanofi

Yellow fever vaccine (live)

Target: Yellow fever

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2026-08-08 (registry estimate)

View Full Clinical Profile → Disease Hub →

Explore Other Vaccine Developers & Sponsors

Compare pipeline volume, phase progression, and modalities across global biopharmaceutical manufacturers.

View All Vaccine Developers →